Cogent Biosciences
COGT
136 hedge funds and large institutions have $814M invested in Cogent Biosciences in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 45 reducing their positions, and 14 closing their positions.
153% more call options, than puts
Call options by funds: $149K | Put options by funds: $59K
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
1% more funds holding
Funds holding: 135 → 136 (+1)
0.48% more ownership
Funds ownership: 107.12% → 107.6% (+0.48%)
4% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 45
5% less capital invested
Capital invested by funds: $859M → $814M (-$44.3M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.6M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$11.5M |
| 3 |
VA
VR Adviser
New York
|
+$10.8M |
| 4 |
CC
Commodore Capital
New York
|
+$5.79M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14M |
| 2 |
PA
Perceptive Advisors
New York
|
-$11.8M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$11.4M |
| 4 |
State Street
Boston,
Massachusetts
|
-$10.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.14M |
COGT Hedge Fund Activity: Q1 2023 in Review
136 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2023, worth a combined $814M — down 5.2% from $859M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new COGT positions and 14 closed out — a net gain of 1 holder — while 43 added to existing stakes and 45 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $28.6M. The largest seller was Fidelity Investments, cutting an estimated $14M.
- 136 institutional investors held Cogent Biosciences (COGT) as of Q1 2023, up from 135 in Q4 2022.
- Funds reported $814M of Cogent Biosciences stock for Q1 2023, down 5.2% quarter-over-quarter.
- 15 funds opened new Cogent Biosciences positions in Q1 2023 and 14 closed out, a net change of +1 holder.
- The largest Cogent Biosciences buyer in Q1 2023 was Point72 Asset Management, an estimated $28.6M added.
- The largest Cogent Biosciences seller in Q1 2023 was Fidelity Investments, an estimated $14M sold.
Based on aggregated 13F filings for Q1 2023.